Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
The results come amid the rollout of Biogen and Eisai's Leqembi, the first drug found to slow the progression of Alzheimer's to win FDA approval.
Biogen's rare genetic disorder drug gets approval in EU
Biogen said on Monday the European Commission has approved its drug for treating a rare genetic disorder that causes progressive damage to the nervous system, in adults and adolescents aged 16 year...
Can Biogen (BIIB) Keep the Beat Streak Alive in Q4 Earnings?
Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.
Stay Ahead of the Game With Biogen Inc. (BIIB) Q4 Earnings: Wall Street's Insights on Key Metrics
Evaluate the expected performance of Biogen Inc. (BIIB) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key ...
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Inc. (BIIB) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $243.72, denoting a -1.66% change from the preceding trading day.
Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The company quits commercializing the controversial Alzheimer's disease drug, Aduhelm.
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
Biogen said its decision to drop Aduhelm, which had a polarizing approval and launch, was "not related to any safety or efficacy concerns."
Biogen halts development of controversial Alzheimer's drug
Biogen Inc. BIIB, -0.18% said Wednesday that it will halt the development and commercialization of its Alzheimer's drug Aduhelm, which drew intense scrutiny of its U.S. regulatory approval process ...
Biogen Inc. (BIIB) Laps the Stock Market: Here's Why
Biogen Inc. (BIIB) closed at $247.52 in the latest trading session, marking a +1.1% move from the prior day.
Biogen Inc. (BIIB) Rises Higher Than Market: Key Facts
Biogen Inc. (BIIB) closed the most recent trading day at $251.68, moving +1.36% from the previous trading session.
These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall Street
Two of Wall Street's favorite Nasdaq-100 stocks for 2024 are communications and media giants. The third stock that analysts think will soar this year is a biotech with a promising new drug on the m...
Biogen Inc. (BIIB) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Biogen Inc. (BIIB) closed at $255.84, marking a -0.83% move from the previous day.
China approves Alzheimer's treatment Leqembi by Eisai and Biogen
Eisai and Biogen said on Tuesday that their Alzheimer's treatment Leqembi had won approval in China, the third country after the United States and Japan.
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic differences.
Related Companies